Exchange: NASDAQ·Updated 04:26 PM EST

About LTGO

About

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

Advertisement|Remove ads.